First Human CRISPR Cure
In November 2019, preliminary results from a CRISPR therapy trial for sickle cell disease and beta-thalassemia showed remarkable success. #CRISPRSickleCell celebrated the first patient becoming transfusion-free after gene editing treatment. The therapy, CTX001, edited patients’ own blood stem cells to produce fetal hemoglobin, which doesn’t sickle.
Clinical Trial Milestones
Between 2020-2022, clinical trials expanded with consistently positive results. Patients who previously required monthly blood transfusions or suffered frequent pain crises became symptom-free. The hashtag tracked each patient success story, with some participants describing the treatment as “life-changing” after decades living with debilitating genetic disease.
FDA Approval & Medical Milestone
In December 2023, the FDA approved Casgevy (CTX001)—the first CRISPR-based therapy for sickle cell disease and beta-thalassemia. #CRISPRSickleCell exploded as this marked CRISPR’s transition from experimental to established medicine. The approval demonstrated that precise gene editing could safely cure previously intractable genetic diseases.
Access & Future Implications
The therapy’s high cost (approximately $2-3 million per patient) raised equity concerns about who could access CRISPR cures. Discussions under the hashtag addressed insurance coverage, global accessibility, and whether gene editing would widen healthcare disparities. The success paved the way for CRISPR therapies targeting other genetic diseases, fundamentally changing medicine’s approach to genetic disorders.
Sources: